2024
Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.
Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.Peer-Reviewed Original ResearchConceptsAcne vulgarisTopical clindamycinTreatment of acne vulgarisManagement of acne vulgarisEmergence of antibiotic-resistant bacteriaAntibiotic-resistant bacteriaTopical agentsAnti-inflammatory propertiesTherapeutic advancesClindamycinClinical studiesTherapeutic outcomesClinical applicationAntimicrobial profileGram-positive bacteriaAnaerobic bacteriaMode of actionVulgarisMonotherapyPublished dataBacteriaTherapyAcneAntibiotics
2023
Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives
Lilly E, Bunick C. Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives. Clinical Cosmetic And Investigational Dermatology 2023, 16: 2473-2479. PMID: 37719935, PMCID: PMC10503504, DOI: 10.2147/ccid.s388608.Peer-Reviewed Original ResearchDisease-specific recommendationsPractical clinical guideEye complicationsClinical reviewLongitudinal careGrowth restrictionClinical guideCurrent treatmentDermatological therapyHereditary disorderCongenital ichthyosesOrphan conditionAffected individualsComplicationsTreatmentThermodysregulationPatientsTherapyInfectionKeratinizationCareCircadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study
Damiani G, Pacifico A, Scoditti E, di Gregorio S, Del Fabbro M, Cozzolino C, Buja A, Mercuri S, Bianchi V, Grada A, Garbarino S, Bunick C. Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study. Dermatology And Therapy 2023, 13: 2229-2246. PMID: 37573289, PMCID: PMC10539244, DOI: 10.1007/s13555-023-00987-z.Peer-Reviewed Original ResearchMinimal erythema dosePsoriatic patientsPsO patientsCohort studyNB-UVBErythema doseNB-UVB therapyLow minimal erythema doseDifferent dietsUVB phototherapyOngoing therapyDiet modulationMedical recordsHealthy controlsRamadan fastingPatientsHealthy individualsDietSignificant differencesPsoriasisMED valuesTherapyCircadian rhythmDosePhototherapy
2022
Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature
Belzer A, Weiss E, Etaee F, Bunick CG, Damsky W, Nelson CA. Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature. Antibiotics 2022, 11: 1398. PMID: 36290055, PMCID: PMC9598652, DOI: 10.3390/antibiotics11101398.Peer-Reviewed Original ResearchSoft tissue infectionsUrinary tract infectionChronic lymphocytic leukemiaGram-negative bacilliTract infectionsImmunocompetent populationTissue infectionsHigh morbidityAplastic anemiaCase reportLymphocytic leukemiaInfectionBacteremiaCurrent standardStenotrophomonas maltophiliaDermatologistsLimited optionsMorbidityPneumoniaPatientsAnemiaTherapyLeukemiaMortalityPrevalence
2020
Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy.
Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.Peer-Reviewed Original ResearchConceptsBiologic therapyTumor necrosis factor alphaFirst-line treatmentTreatment of psoriasisNecrosis factor alphaClinical responseInterleukin-17Interleukin-23Line treatmentPrescribing practicesPsoriasis therapyInflammatory disordersTreatment optionsTherapeutic decisionsClinical dataFactor alphaPatient safetyTherapySignificant differencesBiologic medicinesDrugsEpitope locationMolecular differencesTreatmentMedications